Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Centessa Pharmaceuticals Plc ADR (NQ: CNTA ) 15.89 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Centessa Pharmaceuticals Plc ADR < Previous 1 2 3 4 5 Next > 12 Health Care Stocks Moving In Monday's After-Market Session November 27, 2023 Via Benzinga Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals November 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 November 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting November 02, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Where Centessa Pharmaceuticals Stands With Analysts August 15, 2023 Via Benzinga Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors October 31, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences October 30, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders October 25, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals: Q1 Earnings Insights May 12, 2023 Via Benzinga IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday October 26, 2023 U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Centessa Pharmaceuticals Announces Additions to Senior Leadership Team October 03, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference August 31, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress August 23, 2023 Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 August 14, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's After-Market Session July 13, 2023 Via Benzinga Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 12, 2023 Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. Via Benzinga InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday July 12, 2023 U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session. Via Benzinga Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors July 10, 2023 Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study From Centessa Pharmaceuticals plc Via GlobeNewswire Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows June 23, 2023 Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows Via News Direct Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023 June 21, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023 June 12, 2023 Via Benzinga Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences May 24, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B May 22, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 May 12, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 March 30, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences March 27, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines March 01, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023 March 17, 2023 Via Benzinga Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing February 14, 2023 San Diego, CA -- (SBWIRE) -- 02/14/2023 -- An investigation was announced for investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) concerning potential breaches of fiduciary duties by... Via SBWire Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 06, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
